Science 37 (SNCE) Stock Price, News & Analysis

Company Overview

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina. As of March 11, 2024, Science 37 Holdings, Inc. operates as a subsidiary of eMed, LLC.

Key Stats

• Today's Range: $5.75 to $5.75
• 50-Day Range: $5.68 to $5.75
• 52-Week Range: $3.73 to $12.96
• Volume: N/A
• Average Volume: 43,227 shs
• Market Capitalization: $34.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SNCE Stock Analysis - Frequently Asked Questions

When did Science 37's stock split?

Shares of Science 37 reverse split before market open on Friday, December 8th 2023.The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Science 37 own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Science 37 investors own include Meta Platforms (META), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Broadcom (AVGO), Builders FirstSource (BLDR), Adobe (ADBE) and Advanced Micro Devices (AMD).

Company Calendar

• Today: 7/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SNCE
• CIK: 1819113
• Web: www.lifesciacquisition.com
• Phone: 984-377-3737
• Fax: N/A
• Employees: 460
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($21.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$50.99 million
• Net Margins: -206.86%
• Pretax Margin: -207.00%
• Return on Equity: -83.09%
• Return on Assets: -61.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.17
• Quick Ratio: 4.17

Sales & Book Value

• Annual Sales: $60.26 million
• Price / Sales: 0.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.70 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 5,970,000
• Free Float: 5,564,000
• Market Cap: $34.33 million
• Optionable: Not Optionable
• Beta: 0.55